GO
Loading...

Medicine

More

  • WASHINGTON, Sept 11- Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. It would be sold under the name Saxenda if approved for obesity by the FDA.

  • FDA panel backs Novo Nordisk injection for obesity Thursday, 11 Sep 2014 | 4:16 PM ET

    The FDA first approved the drug, liraglutide, under the brand name Victoza in 2010 as a daily injection for type 2 diabetes, in which the body does not properly use insulin. Danish drugmaker Novo Nordisk now wants the FDA to approve the drug as an obesity treatment based on company studies showing significant weight loss in most patients.

  • WASHINGTON, Sept 11- Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

  • FDA PANEL SAYS NOVO NORDISK'S LIRAGLUTIDE IS SAFE AND EFFECTIVE FOR CHRONICALLY OBESE PATIENTS.

  • JPM's Dimon finishes cancer treatments: Report Thursday, 11 Sep 2014 | 1:09 PM ET
    Jamie Dimon

    Jamie Dimon, who was diagnosed with throat cancer this year, finished his scheduled rounds of radiation and chemotherapy treatment, WSJ reported.

  • Sept 11- JPMorgan Chase& Co CEO Jamie Dimon, who was diagnosed with throat cancer this year, finished his scheduled rounds of radiation and chemotherapy treatment this week, the Wall Street Journal said, citing people familiar with the matter.

  • FDA approves weight-loss drug Contrave Thursday, 11 Sep 2014 | 6:53 AM ET

    Contrave joins two similar drugs from Arena Pharmaceuticals and Vivus Inc. which FDA approved in 2012 after a 13- year drought of new prescription weight-loss medicines. But sales of Vivus' Qsymia and Arena's Belviq have been far below expectations due to limited insurance coverage and high out-of-pocket costs for patients.

  • Sept 11- Ebola is just one of many neglected tropical diseases that badly need attention. The World Health Organization in 2012 designated 17 diseases as priorities for eradication or control:. There is no approved drug but the first vaccine from Sanofi could reach the market late next year.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • Gates Foundations pledges $50M to fight Ebola Wednesday, 10 Sep 2014 | 3:23 PM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    The Bill & Melinda Gates Foundation pledged $50 million to support emergency efforts to contain West Africa's Ebola epidemic.

  • SAN FRANCISCO, Sept 10- Google Inc has acquired the maker of a high-tech spoon that helps people suffering from neurodegenerative tremors to eat, the Internet company's latest foray into the healthcare and biotechnology market.

  • NEW YORK, Sept 9- JPMorgan Chase& Co CEO Jamie Dimon is "feeling fine" with his treatment for throat cancer and is continuing to be involved with the business, the company's chief financial officer said on Tuesday.

  • WASHINGTON, Sept 9- Novo Nordisk's drug liraglutide appears effective in treating obesity, though safety questions remain, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration.

  • Hemispherx to test drugs against Ebola Monday, 8 Sep 2014 | 8:56 AM ET

    Sept 8- Hemispherx Biopharma Inc said it was evaluating two of its drugs against the deadly Ebola virus in collaboration with a unit of the U.S. Department of Defense. The company said it would test Alferon, which is approved for use in the United States to treat genital warts caused by human papilloma virus.

  • Ebola outbreak stirs anger in fragile Liberia Saturday, 6 Sep 2014 | 5:00 AM ET

    *Anger mounts as Ebola death toll tops 1,000 in Liberia. MONROVIA/ DAKAR, Sept 6- When a starving Ebola patient escaped from a treatment centre in Monrovia and staggered through a crowded market in search of food, bystanders who scattered in his path voiced their anger not at him but at Liberia's president.

  • Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.

  • Keryx kidney drug gets OK for dialysis patients Friday, 5 Sep 2014 | 11:52 AM ET

    NEW YORK— Keryx Biopharmaceuticals received U.S. approval Friday for a new pill to treat complications of kidney disease, though warning language in the drug's label surprised some analysts.

  • Keryx Biopharma gets U.S. approval for kidney drug Friday, 5 Sep 2014 | 11:28 AM ET

    Sept 5- Keryx Biopharmaceuticals Inc won the U.S. Food and Drug Administration approval for its drug to lower phosphate levels in patients with chronic kidney disease who are already on dialysis. It affects more than 20 million adults in the United States, according to the U.S. Centers for Disease Control and Prevention.

  • SYDNEY, Sept 5- Mining companies are beefing up protection against the spreading Ebola virus in West Africa while maintaining investment in new projects in a region with vast untapped mineral wealth.

  • Sept 4- Drug developer Recro Pharma Inc said it planned to end a mid-stage trial of its lead post-operative pain drug because it did not expect the trial to achieve statistically significant results under its current design. The company's shares fell as much as 20 percent in extended trading.